The European Medicines Agency (EMA) has just concluded a review of Post SSRI Sexual Dysfunction (PSSD) and Persistent Genital Arousal Disorder (PGAD) after the discontinuation of SSRIs and SNRIs (antidepressants). On Thursday 16 May, the safety Committee of EMA concluded that “sexual dysfunction, which is known to occur with treatment with SSRIs and SNRIs and usually resolves after treatment has stopped, can be long-lasting in some patients, even after treatment withdrawal.” EMA says that it is currently not known how long these symptoms can persist, and the issue will continue to be closely monitored. The outcome of the review was made public on EMA’s website on 11 June 2019.